Association between methylation of BIN1 promoter in peripheral blood and preclinical Alzheimer’s disease
Open Access
- 2 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Translational Psychiatry
- Vol. 11 (1), 1-13
- https://doi.org/10.1038/s41398-021-01218-9
Abstract
The bridging integrator 1 (BIN1) gene is the second most important susceptibility gene for late-onset Alzheimer’s disease (LOAD) after apolipoprotein E (APOE) gene. To explore whether the BIN1 methylation in peripheral blood changed in the early stage of LOAD, we included 814 participants (484 cognitively normal participants [CN] and 330 participants with subjective cognitive decline [SCD]) from the Chinese Alzheimer’s Biomarker and LifestylE (CABLE) database. Then we tested associations of methylation of BIN1 promoter in peripheral blood with the susceptibility for preclinical AD or early changes of cerebrospinal fluid (CSF) AD-related biomarkers. Results showed that SCD participants with significant AD biological characteristics had lower methylation levels of BIN1 promoter, even after correcting for covariates. Hypomethylation of BIN1 promoter were associated with decreased CSF Aβ42 (p = 0.0008), as well as increased p-tau/Aβ42 (p = 0.0001) and t-tau/Aβ42 (p < 0.0001) in total participants. Subgroup analysis showed that the above associations only remained in the SCD subgroup. In addition, hypomethylation of BIN1 promoter was also accompanied by increased CSF p-tau (p = 0.0028) and t-tau (p = 0.0130) in the SCD subgroup, which was independent of CSF Aβ42. Finally, above associations were still significant after correcting single nucleotide polymorphic sites (SNPs) and interaction of APOE ɛ4 status. Our study is the first to find a robust association between hypomethylation of BIN1 promoter in peripheral blood and preclinical AD. This provides new evidence for the involvement of BIN1 in AD, and may contribute to the discovery of new therapeutic targets for AD.Keywords
Funding Information
- National Natural Science Foundation of China (91849126)
This publication has 44 references indexed in Scilit:
- BIN1 Is Decreased in Sporadic but Not Familial Alzheimer’s Disease or in AgingPLOS ONE, 2013
- Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathologyMolecular Psychiatry, 2013
- Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's diseaseNature Genetics, 2011
- Identification of Novel Loci for Alzheimer Disease and Replication of CLU, PICALM, and BIN1 in Caribbean Hispanic IndividualsArchives of Neurology, 2011
- Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of agingNeurobiology of Aging, 2010
- Genome-wide Analysis of Genetic Loci Associated With Alzheimer DiseaseJama-Journal Of The American Medical Association, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's diseaseProceedings of the National Academy of Sciences of the United States of America, 2009
- Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene databaseNature Genetics, 2007
- Heritability for Alzheimer's Disease: The Study of Dementia in Swedish TwinsThe Journals of Gerontology: Series A, 1997